Search results
Results from the WOW.Com Content Network
Here are additional clues for each of the words in today's Mini Crossword. NYT Mini Across Hints 1 Across: Square on a wall calendar, or a fun thing you might put on the calendar — HINT: It ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Genentech is still producing drugs and treatments to this day, and some of his policies, such as allowing company scientists to publish, are still in place. [ 6 ] [ 5 ] [ 8 ] Genentech scored many firsts under Swanson's leadership, such as developing the first drug produced via genetic engineering, being the first biotechnology company to go ...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]
For premium support please call: 800-290-4726 more ways to reach us